- Home
- CRWV vs ZTS Comparison
CRWV vs ZTS Comparison
Compare CRWV & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWV
- ZTS
- Stock Information
- Founded
- CRWV 2017
- ZTS 1952
- Country
- CRWV United States
- ZTS United States
- Employees
- CRWV N/A
- ZTS N/A
- Industry
- CRWV
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- CRWV
- ZTS Health Care
- Exchange
- CRWV NYSE
- ZTS Nasdaq
- Market Cap
- CRWV 78.3B
- ZTS 73.2B
- IPO Year
- CRWV 2025
- ZTS 2013
- Fundamental
- Price
- CRWV $115.62
- ZTS $152.01
- Analyst Decision
- CRWV Hold
- ZTS Buy
- Analyst Count
- CRWV 16
- ZTS 8
- Target Price
- CRWV $85.07
- ZTS $204.00
- AVG Volume (30 Days)
- CRWV 11.8M
- ZTS 3.1M
- Earning Date
- CRWV 08-14-2025
- ZTS 08-05-2025
- Dividend Yield
- CRWV N/A
- ZTS 1.31%
- EPS Growth
- CRWV N/A
- ZTS 7.32
- EPS
- CRWV N/A
- ZTS 5.57
- Revenue
- CRWV $2,708,374,000.00
- ZTS $9,286,000,000.00
- Revenue This Year
- CRWV $144.33
- ZTS $3.45
- Revenue Next Year
- CRWV $134.59
- ZTS $6.16
- P/E Ratio
- CRWV N/A
- ZTS $27.30
- Revenue Growth
- CRWV 17009.12
- ZTS 6.32
- 52 Week Low
- CRWV $33.52
- ZTS $139.70
- 52 Week High
- CRWV $187.00
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- CRWV N/A
- ZTS 42.20
- Support Level
- CRWV N/A
- ZTS $147.25
- Resistance Level
- CRWV N/A
- ZTS $154.04
- Average True Range (ATR)
- CRWV 0.00
- ZTS 3.06
- MACD
- CRWV 0.00
- ZTS 0.01
- Stochastic Oscillator
- CRWV 0.00
- ZTS 32.78
About CRWV COREWEAVE INC
CoreWeave Inc is a modern cloud infrastructure technology company that offers the CoreWeave Cloud Platform which consists of proprietary software and cloud services that deliver the automation and efficiency needed to manage complex AI infrastructure at scale. Its platform supports the development and use of ground-breaking models and the delivery of the next generation of AI applications that are changing the way of living and working across the globe.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.